Pricing Availability   Qty
Description: Potent and selective CCR10 antagonist
Chemical Name: N-[(1R)-3-(2-Cyano-1H-pyrrol-1-yl)-1-[(4-methyl-1-piperidinyl)carbonyl]propyl]-1H-indole-4-sulfonamide
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for BI-6901

BI-6901 is a potent and selective CCR10 antagonist (IC50 = 1 - 25 nM). BI-6901 inhibits CCL27-dependent chemotaxis of Ba/F3 cells (IC50 = 1 nM) and reduces inflammation in a DNFB-stimulated animal model of contact hypersensitivity.

Technical Data for BI-6901

M. Wt 453.56
Formula C23H27N5O3S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 2040401-92-9
PubChem ID 131801164
Smiles CC1CCN(C([C@H](NS(=O)(C2=C3C=CNC3=CC=C2)=O)CCN4C=CC=C4C#N)=O)CC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for BI-6901

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 45.36 100
ethanol 45.36 100

Preparing Stock Solutions for BI-6901

The following data is based on the product molecular weight 453.56. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.2 mL 11.02 mL 22.05 mL
5 mM 0.44 mL 2.2 mL 4.41 mL
10 mM 0.22 mL 1.1 mL 2.2 mL
50 mM 0.04 mL 0.22 mL 0.44 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for BI-6901

References are publications that support the biological activity of the product.

Abeywardane et al (2016) N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity. Bioorg.Med.Chem.Lett. 26 5277 PMID: 27692854

If you know of a relevant reference for BI-6901, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Chemokine CC Receptor Antagonists

Keywords: BI-6901, BI-6901 supplier, BI6901, eut22, potent, selective, chemokines, receptors, antagonists, chemotaxis, inflammation, antiinflammatory, anti-inflammatory, CCR10, Chemokine, CC, Receptors, 6141, Tocris Bioscience

Citations for BI-6901

Citations are publications that use Tocris products.

Currently there are no citations for BI-6901. Do you know of a great paper that uses BI-6901 from Tocris? Please let us know.

Reviews for BI-6901

There are currently no reviews for this product. Be the first to review BI-6901 and earn rewards!

Have you used BI-6901?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.